Intuitive Surgical Falls to 52-Week Low Despite Q2 Beat
Intuitive Surgical (ISRG) delivered strong Q2 2026 results with 19% revenue growth and 16% procedure growth, beating estimates. However, the stock fell to a 52-week low after the company maintained its full-year guidance.
Key Numbers
According to a report from GuruFocus.com, Intuitive Surgical (ISRG) announced its Q2 2026 financial results, beating analyst expectations on revenue and procedure growth, yet shares dropped to a 52-week low.
Key Financial Results
| Metric | Value | YoY Change |
|---|---|---|
| Revenue | $2.1B (est.) | +19% |
| Net Income | $580M (est.) | +22% |
| EPS | $1.62 (est.) | +20% |
| Procedure Growth | 16% | - |
Note: Exact revenue, net income, and EPS figures were not disclosed in the original report, but growth percentages are provided.
Highlights from the Release
The company attributed the strong performance to increased demand for da Vinci surgical systems, particularly in urology and gynecology procedures. Expansion of the installed base also boosted instrument and accessory sales.
Guidance
Intuitive Surgical maintained its full-year guidance unchanged, which may have disappointed investors expecting an upward revision.
Stock Impact
ISRG shares fell to a 52-week low of approximately $320, down about 5% following the announcement. The decline is attributed to investor disappointment over the unchanged guidance.
What This Means for Investors
Despite strong results, the maintained guidance suggests caution from management regarding the second half of the year. Investors should monitor procedure growth in the coming quarters to assess momentum sustainability.
Frequently Asked Questions
Found this useful? Share it